Cynthia Marie-Claire

List of Publications by Year
in descending order

60 papers	2,046 citations	257450 24 h-index	265206 42 g-index
61 all docs	61 docs citations	61 times ranked	3092 citing authors

#	Article	IF	Citations
1	Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multiâ€disciplinary literature review and agenda for future research from the ISBD task force on chronobiology. Bipolar Disorders, 2022, 24, 232-263.	1.9	36
2	Occurrence and severity of cocaine-induced hallucinations: Two distinct phenotypes with shared clinical factors but specific genetic risk factors. Drug and Alcohol Dependence, 2022, 232, 109270.	3.2	2
3	Influence of childhood maltreatment on prevalence, onset, and persistence of psychiatric comorbidities and suicide attempts in bipolar disorders. European Psychiatry, 2022, 65, 1-32.	0.2	8
4	Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study. Pharmaceuticals, 2022, 15, 133.	3.8	5
5	Association between childhood maltreatment and the clinical course of bipolar disorders: A survival analysis of mood recurrences. Acta Psychiatrica Scandinavica, 2022, 145, 373-383.	4.5	9
6	The molecular pathophysiology of mood disorders: From the analysis of single molecular layers to multi-omic integration. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 116, 110520.	4.8	6
7	Telomere length and mitochondrial DNA copy number in bipolar disorder: identification of a subgroup of young individuals with accelerated cellular aging. Translational Psychiatry, 2022, 12, 135.	4.8	15
8	Clustering suicidal phenotypes and genetic associations with brain-derived neurotrophic factor in patients with substance use disorders. Translational Psychiatry, 2021, 11, 72.	4.8	4
9	Biomarkers to predict staging and treatment response in opioid dependence: A narrative review. Drug Development Research, 2021, 82, 668-677.	2.9	1
10	Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers. Frontiers in Psychiatry, 2021, 12, 565617.	2.6	5
11	Network of co-expressed circadian genes, childhood maltreatment and sleep quality in bipolar disorders. Chronobiology International, 2021, 38, 986-993.	2.0	7
12	Mini review: Recent advances on epigenetic effects of lithium. Neuroscience Letters, 2021, 761, 136116.	2.1	5
13	A Comparison of Different Approaches to Clinical Phenotyping of Lithium Response: A Proof of Principle Study Employing Genetic Variants of Three Candidate Circadian Genes. Pharmaceuticals, 2021, 14, 1072.	3.8	2
14	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. Translational Psychiatry, 2021, 11, 606.	4.8	25
15	Lithium effects on serine-threonine kinases activity: High throughput kinomic profiling of lymphoblastoid cell lines from excellent-responders and non-responders bipolar patients. World Journal of Biological Psychiatry, 2020, 21, 317-324.	2.6	4
16	Childhood maltreatment and HPA axis gene expression in bipolar disorders: A gene network analysis. Psychoneuroendocrinology, 2020, 120, 104753.	2.7	6
17	A DNA methylation signature discriminates between excellent and non-response to lithium in patients with bipolar disorder type 1. Scientific Reports, 2020, 10, 12239.	3.3	21
18	Translational study of the whole transcriptome in rats and genetic polymorphisms in humans identifies LRP1B and VPS13A as key genes involved in tolerance to cocaine-induced motor disturbances. Translational Psychiatry, 2020, 10, 381.	4.8	6

#	Article	IF	Citations
19	QT length during methadone maintenance treatment: geneÂÃ—Âdose interaction. Fundamental and Clinical Pharmacology, 2019, 33, 96-106.	1.9	10
20	Determination of sets of covariating gene expression using graph analysis on pairwise expression ratios. Bioinformatics, 2019, 35, 258-265.	4.1	9
21	Selecting reference genes in RT-qPCR based on equivalence tests: a network based approach. Scientific Reports, 2019, 9, 16231.	3.3	15
22	Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study. Journal of Neuroimmunology, 2019, 334, 576993.	2.3	5
23	Dopamine (DRD 2) and Serotonin (HTR 2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. Fundamental and Clinical Pharmacology, 2019, 33, 355-364.	1.9	11
24	A tutorial on conducting genomeâ€•wide association studies: Quality control and statistical analysis. International Journal of Methods in Psychiatric Research, 2018, 27, e1608.	2.1	465
25	Lithium response in bipolar disorders and core clock genes expression. World Journal of Biological Psychiatry, 2018, 19, 619-632.	2.6	45
26	DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder. International Journal of Molecular Sciences, 2018, 19, 3026.	4.1	38
27	Molecular Signatures of Lithium Treatment: Current Knowledge. Pharmacopsychiatry, 2018, 51, 212-219.	3.3	18
28	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	2.6	28
29	Lithium response in bipolar disorder: No difference in GADL1 gene expression between cell lines from excellent-responders and non-responders. Psychiatry Research, 2017, 251, 217-220.	3.3	9
30	Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives. Pharmacogenomics, 2017, 18, 1359-1372.	1.3	8
31	Lithium Response Variability: New Avenues and Hypotheses. , 2017, , 157-178.		2
32	Circadian genes and lithium response in bipolar disorders: associations with <scp>PPARGC1A</scp> (<scp>PGC</scp>â€•1<i>Î±</i>) and <scp>RORA</scp>. Genes, Brain and Behavior, 2016, 15, 660-668.	2.2	37
33	Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts. Epigenomics, 2016, 8, 181-195.	2.1	17
34	Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties. Psychopharmacology, 2014, 231, 3139-3149.	3.1	30
35	Comparison of the transcriptional responses induced by acute morphine, methadone and buprenorphine. European Journal of Pharmacology, 2013, 711, 10-18.	3.5	8
36	Transport of Biogenic Amine Neurotransmitters at the Mouse Bloodâ€“Retina and Bloodâ€“Brain Barriers by Uptake1 and Uptake2. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1989-2001.	4.3	34

#	Article	IF	Citations
37	Chronic and intermittent morphine treatment differently regulates opioid and dopamine systems: a role in locomotor sensitization. Psychopharmacology, 2011, 216, 297-303.	3.1	39
38	PRECLINICAL STUDY: Modulation of MDMAâ€induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice. Addiction Biology, 2009, 14, 245-252.	2.6	14
39	Effect of chronic exposure to morphine on the rat bloodâ€“brain barrier: focus on the Pâ€glycoprotein. Journal of Neurochemistry, 2008, 107, 647-657.	3.9	60
40	Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice. Brain Research, 2008, 1211, 1-5.	2.2	43
41	Characteristics of dual specificity phosphatases mRNA regulation by 3,4-methylenedioxymethamphetamine acute treatment in mice striatum. Brain Research, 2008, 1239, 42-48.	2.2	14
42	Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice. Neuropharmacology, 2008, 54, 1107-1111.	4.1	14
43	Effects of chronic morphine and morphine withdrawal on gene expression in rat peripheral blood mononuclear cells. Neuropharmacology, 2008, 55, 1347-1354.	4.1	32
44	Sensitization to the conditioned rewarding effects of morphine modulates gene expression in rat hippocampus. Neuropharmacology, 2007, 52, 430-435.	4.1	16
45	Rnd family genes are differentially regulated by 3,4-methylenedioxymethamphetamine and cocaine acute treatment in mice brain. Brain Research, 2007, 1134, 12-17.	2.2	29
46	Expression of drug transporters at the bloodâ€“brain barrier using an optimized isolated rat brain microvessel strategy. Brain Research, 2007, 1134, 1-11.	2.2	125
47	Regulation of genes involved in dopamine transporter modulation by acute cocaine in rat striatum. Neuroscience Letters, 2006, 398, 235-240.	2.1	11
48	Analysis of transcriptional responses in the mouse dorsal striatum following acute 3,4-methylenedioxymethamphetamine (ecstasy): Identification of extracellular signal-regulated kinase-controlled genes. Neuroscience, 2006, 137, 473-482.	2.3	17
49	Cytoskeletal Genes Regulation by Chronic Morphine Treatment in Rat Striatum. Neuropsychopharmacology, 2004, 29, 2208-2215.	5.4	86
50	Further evidence that the CCK₂ receptor is coupled to two transduction pathways using siteâ€directed mutagenesis. Journal of Neurochemistry, 2003, 85, 454-461.	3.9	25
51	Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. British Journal of Pharmacology, 2003, 140, 831-838.	5.4	111
52	General function of N-terminal propeptide on assisting protein folding and inhibiting catalytic activity based on observations with a chimeric thermolysin-like protease. Biochemical and Biophysical Research Communications, 2003, 301, 1093-1098.	2.1	38
53	Fos but not Cart (cocaine and amphetamine regulated transcript) is overexpressed by several drugs of abuse: a comparative study using real-time quantitative polymerase chain reaction in rat brain. Neuroscience Letters, 2003, 345, 77-80.	2.1	62
54	Folding pathway mediated by an intramolecular chaperone: the structural and functional characterization of the aqualysin I propeptide. Journal of Molecular Biology, 2001, 305, 151-165.	4.2	46

#	Article	IF	Citations
55	Exploration of theS?1 subsite of neprilysin: A joined molecular modeling and site-directed mutagenesis study. , 2000, 39, 365-371.		11
56	The prosequence of thermolysin acts as an intramolecular chaperone when expressed in trans with the mature sequence in Escherichia coli 1 1Edited by A. R. Fersht. Journal of Molecular Biology, 1999, 285, 1911-1915.	4.2	62
57	Differences in transition state stabilization between thermolysin (EC 3.4.24.27) and neprilysin (EC) Tj ETQq1 1 0.784314 rgBT /Overlock	2.8	28
58	Characterization of Glu350as a Critical Residue Involved in the N-Terminal Amine Binding Site of Aminopeptidase N (EC 3.4.11.2):Â Insights into Its Mechanism of Action. Biochemistry, 1998, 37, 686-692.	2.5	111
59	Intramolecular Processing of Prothermolysin. Journal of Biological Chemistry, 1998, 273, 5697-5701.	3.4	44
60	Evidence by Site-Directed Mutagenesis That Arginine 203 of Thermolysin and Arginine 717 of Neprilysin (Neutral Endopeptidase) Play Equivalent Critical Roles in Substrate Hydrolysis and Inhibitor Binding. Biochemistry, 1997, 36, 13938-13945.	2.5	41